cIAP-2/HIAP-1 Antibody

cIAP2 (API2, BIRC3, HIAP2, MIHC) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria dependent and independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including cIAP2, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubiquitination. Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. The IAPs, including cIAP2, have widespread tissue protein expression, with expression levels and subcellular localization patterns differing depending on the cell lineage (see Vischioni et al. 2005 for a comprehensive study). cIAP2-MALT (API2-MALT1) fusion proteins have been implicated in the molecular pathology of mucosa associated lymphoid tissue (MALT) lymphoma (reviewed in Hosokawa, 2005). AP12-MALT fusion proteins are found in a subset of patients with MALT lymphoma. They are generated by chromosomal translocations whereby the N-terminal portion of AP12 (including the BIR domains) is linked to the C-terminal portion of MALT1 (containing at least an immunoglobulin-like domain and a caspase domain). Several variants of the API2-MALT1 fusion proteins can occur in MALT1 lymphoma patients depending on the chromosomal breakpoints. It is thought that AP12-MALT1 can enhance the activation of NK-kB signaling, which may be relevant to the pathology of MALT lymphomas. This antibody recognizes cIAP2, human cIAP2 is a 604 amino acid protein. This antibody should also recognize AP12-MALT1 fusion proteins assuming that they contain the cIAP2 peptide sequence (QDFSALMRSSYHCAMNNENAR) used for immunogen. The AP12-MALT1 fusion proteins is listed as an 1140 amino acid protein, GenBank no. AAD46161.1. However, users should keep in mind that the actual amino acid length of AP12-MALT1 fusion proteins may vary depending on the chromosomal breakpoints

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: IF/IHC.

Showing Publication 1 - 1 of 1.

Publication using NB100-56132	Applications	Species
Jo SJ, Park PG, Cha HR et al. Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway Oncotarget. 2017-10-03 [PMID: 29108265] (IF/IHC, Human)	IF/IHC	Human

Array NB100-56132

• cIAP-2/HIAP-1 Antibodies
• cIAP-2/HIAP-1 Lysates
• cIAP-2/HIAP-1 Proteins
• cIAP-2/HIAP-1 Proteins and Enzyme